Bristol-Myers Squibb Company

Bristol Myers Squibb (BMS) is a multinational biopharmaceutical company that develops and manufactures innovative medicines for serious diseases. Headquartered in Princeton, New Jersey, it is consistently ranked among the largest pharmaceutical companies globally.

Therapeutic areas

BMS's primary focus is on developing drugs for the treatment of:

• Oncology and hematology: Cancer and blood disorders
• Cardiovascular disease: Heart and circulatory conditions
• Immunology: Autoimmune diseases
• Neuroscience: Neurological disorders
• Fibrotic diseases: Conditions involving the formation of excess fibrous connective tissue

Key products

Some of the most popular and significant drugs in the company's portfolio include:

• Eliquis® (apixaban): An anticoagulant used to reduce the risk of stroke and treat deep vein thrombosis (DVT).
• Opdivo® (nivolumab): An immunotherapy drug for treating various cancers, including melanoma, lung, and head and neck cancer.
• Pomalyst® / Imnovid® (pomalidomide): A treatment for multiple myeloma.
• Orencia® (abatacept): Used for treating rheumatoid arthritis and psoriatic arthritis.
• Yervoy® (ipilimumab): An immunotherapy for melanoma.

Recent news and strategy

• Recent acquisitions: In March 2024, BMS completed its $14 billion acquisition of Karuna Therapeutics, gaining access to the investigational schizophrenia drug KarXT. This followed several other significant purchases, including Mirati Therapeutics in January 2024 and RayzeBio in 2024, to bolster its oncology pipeline.
• Key partnerships: In June 2025, BMS announced an $11 billion partnership with BioNTech to develop new experimental cancer drugs, combining BioNTech's scientific platforms with BMS's expertise in immuno-oncology.
• Clinical trial results: The company has reported both positive and negative results from recent clinical trials. A Phase 3 trial for the adjuvant treatment of melanoma, RELATIVITY-098, did not meet its primary endpoint, but the Phase 3 CheckMate -816 trial for lung cancer showed improved overall survival.
• Portfolio focus: BMS is actively pursuing a "string of pearls" strategy, using targeted acquisitions and partnerships to build a portfolio of innovative medicines and address patent expiration impacts on some of its legacy drugs. As part of this strategy, in September 2025, the company sold its controlling stake in its first U.S.-China pharmaceutical joint venture to better focus on its core innovative medicines business.
• Financial performance: For the first quarter of 2025, BMS reported strong growth in its portfolio of newer products, which helped offset revenue declines from legacy drugs like Revlimid due to generic competition. The company raised its 2025 revenue and non-GAAP earnings per share guidance.

Regulatory approval

• European Union approval: In September 2025, BMS received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for its Opdivo regimen for treating resectable non-small cell lung cancer.
• Recent FDA action: The U.S. FDA has recently accepted a supplemental biologics license application for Opdivo plus Yervoy for treating certain types of microsatellite instability-high or mismatch repair deficient tumors.

Corporate social responsibility

BMS emphasizes its commitment to patients and employees. It is involved in sustainability initiatives, promoting diversity and inclusion, and supporting cancer research through events like the Country 2 Country 4 Cancer cycle race.

‍